Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 : a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Salwender, Hans; Bertsch, Uta; Weisel, Katja; Duerig, Jan; Kunz, Christina; Benner, Axel; Blau, Igor W.; Raab, Marc Steffen; Hillengass, Jens; Hose, Dirk; Huhn, Stefanie; Hundemer, Michael; Andrulis, Mindaugas; Jauch, Anna; Seidel-Glaetzer, Andrea; Lindemann, Hans-Walter; Hensel, Manfred; Fronhoffs, Stefan; Martens, Uwe; Hansen, Timon; Wattad, Mohammed; Graeven, Ullrich; Munder, Markus; Fenk, Roland; Haenel, Mathias; Scheid, Christof; Goldschmidt, Hartmut

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 : a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Autor(en):

Salwender, Hans; Bertsch, Uta; Weisel, Katja; Duerig, Jan; Kunz, Christina; Benner, Axel; Blau, Igor W.; Raab, Marc Steffen; Hillengass, Jens; Hose, Dirk; Huhn, Stefanie; Hundemer, Michael; Andrulis, Mindaugas; Jauch, Anna; Seidel-Glaetzer, Andrea; Lindemann, Hans-Walter; Hensel, Manfred; Fronhoffs, Stefan; Martens, Uwe; Hansen, Timon; Wattad, Mohammed; Graeven, Ullrich; Munder, Markus; Fenk, Roland; Haenel, Mathias; Scheid, Christof; Goldschmidt, Hartmut

Tübinger Autor(en):

Weisel, Katja

Erschienen in:

Bmc Cancer (2019), Bd. 19, Article 504

Verlagsangabe:

Bmc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1186/s12885-019-5600-x

ISSN:

1471-2407